focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.50
Bid: 23.20
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 2.80 (12.069%)
Open: 24.50
High: 0.00
Low: 0.00
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SkinBio launches food supplement on Amazon

Thu, 30th Nov 2023 14:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Iofina PLC - Colorado, US-based manufacturing company that specialises in the production of iodine and the manufacture of speciality chemical derivatives - Reminds investors that the ramp-up of IO9, its iodine plant in Western Oklahoma, took longer than expected. Says that recent upgrades have improved the flow of brine water to the plant, adding that it has been able to steadily increase crystalline iodine production following the completion of this work. Confirms that the plant is now operating within its expected output range. Expects second-half production at the bottom, or very marginally below, the bottom end of the forecast range of 325 to 350 metric tonnes.

----------

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Says that its AxisBiotix-Ps food supplement will launch on Amazon.co.uk from December 6. AxisBiotix-Ps is designed to help alleviate sensitive skin conditions like psoriasis. SkinBio Therapeutics says the sale of the product on Amazon is a key part of its commercialisation strategy, and that it aims to extend product availability through other Amazon country sites. Says management is already proactively seeking to expand online sales of AxisBiotix-Ps into France, Italy, and Spain, where the product has regulatory clearance.

----------

Oncimmune Holdings PLC - Nottingham, England-based immunodiagnostics developer - Notes strategic progress towards end of first quarter, including contracts signed for four new projects, with additional contracts approved by customers and due to be signed in the second quarter. Says three of the contracts are with major pharmaceutical companies who were existing customers, while the fourth is with a new customer focused on "high throughput drug discovery". Chief Executive Officer Martin Gouldstone says: "I am encouraged to see the commercial traction already being made on delivering our strategy, including our ability to expand the application of our ImmunoINSIGHTS platform into drug discovery as well as clinical trials. I have recently spent time discussing our strategy with some of our key stakeholders and have been pleased to see how well it has been received, also allowing us to recruit top talent to further accelerate our ability to deliver on it."

----------

Baron Oil PLC - London-based oil & gas exploration and appraisal company - Celebrates as its wholly-owned owned subsidiary, SundaGas Banda Unipessoal Lda, gets project classification from Autoridade Nacional do Petroleo for the Chuditch field. Sundagas is the operator of the TL-SO-19-16 production sharing contract, offshore Timor-Leste, while ANP is the Timor-Leste government regulator for oil and gas. The next step is the submission of a term of reference, including initial public consultations. Baron Oil adds that, regarding drilling, a Timorese drilling engineer has been recruited to join the SundaGas well operations team, and expressions of interest are being sought from in-country suppliers to provide services from the Timorese private sector. It also continues to evaluate all potential options for gas export from the Chuditch field in order to be able to fast track the concept selection processes.

----------

Arkle Resources PLC - Exploration company, with principal assets in Irish gold and zinc exploration licences - Says a drilling programme at Inishowen in County Donegal is due to begin this week. The drilling, which is a follow-up to work at the Meeneragh target, will test the main gold bearing outcrop. Four holes are planned in this phase from two drill pads drilling at minus 45 and minus 70 degrees. The focus of the programme will be on the main vein target discovered earlier. Chair John Teeling says: "It is good to get back on the ground again at Inishowen. This new round of drilling will test to see if we can trace the main vein along strike and at depth. We found high grade gold in the area and we now aim to expand this."

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
10 May 2019 12:59

Oncimmune begins study to bring 'EarlyCDT-Lung' to China

(Sharecast News) - Oncimmune Holdings, alongside its partner Genostics Company, announced the start of a multi-centre case control study on early lung cancer detection for screening and nodules in the People's Republic of China on Friday, using an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells in Asian populations.

Read more
10 May 2019 11:36

Oncimmune And Genostics Initiate Trial Of EarlyCDT-Lung In China

LONDON (Alliance News) - Oncimmune Holdings PLC and Genostics Co Ltd on Friday said a multi-centre case control study on early lung cancer detection in China has started.The company said is

Read more
5 Apr 2019 15:10

Oncimmune inks distribution deal for lung cancer test in Portugal

(Sharecast News) - Personalised immunodiagnostics developer Oncimmune Holdings has signed an exclusive agreement for the distribution of its 'EarlyCDT-Lung' test kit in Portugal with Sabartech, its existing distributor in Spain, it announced on Friday.

Read more
5 Apr 2019 10:04

Oncimmune Signs Lung Cancer Test Kit Distribution Deal With Sabartech

LONDON (Alliance News) - Cancer diagnostics company Oncimmune Holdings PLC on Friday said it has signed an exclusive agreement for the distribution of its lung cancer test kit in Portgual with can

Read more
2 Apr 2019 10:50

Oncimmune strengthens scientific board with addition of Parag Mallick

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the appointment of Dr Parag Mallick - an associate professor of radiology at Stanford University - to its scientific board on Tuesday.

Read more
19 Mar 2019 12:19

Oncimmune Buys Protagen Diagnostics In EUR4 Million All-Share Deal (ALLISS)

LONDON (Alliance News) - Cancer testing firm Oncimmune Holdings PLC said Tuesday it acquired protein biomarker laboratory Protagen Diagnostics AG for EUR4.1 million in an all-share will buy the of

Read more
19 Mar 2019 09:10

Oncimmune acquires Protagen Diagnostics in £4.11m deal

(Sharecast News) - Oncimmune Holdings has acquired Protagen Diagnostics for a total consideration of up to £4.11m, it announced on Tuesday, to be paid by the allotment of up to 2,635,910 Oncimmune ordinary shares at 156p each 0 a premium of 71% to the closing mid-market price on 18 March.

Read more
13 Feb 2019 10:45

Oncimmune Loss Widens In First Half On Administrative Costs

LONDON (Alliance News) - Cancer diagnostics business Oncimmune Holdings PLC on Wednesday said its loss widened in the first half its year on higher administrative expenses.In the six months

Read more
13 Feb 2019 09:20

Oncimmune Holdings' loss deepens on spiralling costs

(Sharecast News) - Oncimmune Holdings reported a widened interim loss on Wednesday as increases to research & development costs and administrative costs outweighed a rise in revenue.

Read more
20 Dec 2018 16:27

Oncimmune buoyed by US distribution deal for blood tests

(Sharecast News) - Oncimmune Holdings made gains on Thursday after it entered an agreement with America's Choice Provider Network to expand access to its EarlyCDT-Lung and EarlyCDT-Liver blood tests.

Read more
6 Dec 2018 17:39

Oncimmune Appoints Former Tusk Therapeutics CFO Matthew Hall To Board

LONDON (Alliance News) - Cancer diagnostics firm Oncimmune Holdings PLC on Thursday said its has appointed former Tusk Therapeutics Ltd Chief Financial Officer Matthew Hall as finance will replace

Read more
28 Nov 2018 11:57

Oncimmune signs sales deals in multiple countries for 'EarlyCDT-Lung' test

(Sharecast News) - Immunodiagnostics developer Oncimmune Holdings has signed exclusive agreements for the distribution of its 'EarlyCDT-Lung' test in Germany with hrmed.tech, in France with Eurobio Scientific, and in Italy with BSN, it announced on Wednesday.

Read more
31 Oct 2018 09:19

Oncimmune Annual Loss Deepens As Costs Hurt, Chases Cancer Test Deals

LONDON (Alliance News) - Oncimmune Holdings PLC said Wednesday its full year loss deepened on higher costs as it continues to chase new distribution deals for its cancer detection blood test the a

Read more
1 Oct 2018 12:47

Oncimmune inks multiple new distribution agreements

(Sharecast News) - Oncimmune revealed on Monday that it had signed multiple new distribution agreements for its EarlyCDT-Lung test as part of an early morning trading update.

Read more
25 Sep 2018 17:21

Oncimmune Says Lung Cancer Blood Test Outperforms Risk Calculator

LONDON (Alliance News) - Pharma company Oncimmune Holdings PLC on Tuesday said its lung cancer blood test, EarlyCDT-Lung, has proven to be more effective than a standard risk produced a positive a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.